Juan Tamariz Loor, MD
Critical Care Medicine · Bend, ORNPI 1225286586
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,203 of the $6,710 with a category attached, or 62.6%. Intuitive Surgical accounts for 81.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $3,921 and has fallen 53.6% since, to $1,818 in 2025. Among critical care medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $111.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- GSK$446
- AstraZeneca$160
- Sanofi-aventis U.S. LLC$154
- Actelion Pharmaceuticals US, Inc.$86
- United Therapeutics Corporation$73
- plus $300 from 10 others
What the payments were for
- Travel & lodging$1,23818%
- Food & beverage$1,26919%
- Education$4,20363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $5,490 |
| GSK | 15 | $446 |
| AstraZeneca | 4 | $160 |
| Sanofi-aventis U.S. LLC | 2 | $154 |
| Actelion Pharmaceuticals US, Inc. | 4 | $86 |
| United Therapeutics Corporation | 1 | $73 |
| Genentech USA, Inc. | 5 | $51 |
| Insmed, Inc. | 3 | $49 |
| Boehringer Ingelheim | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Electromed, Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Bayer | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,316
- NUCALA$242
How this compares
$6,710 in reported general payments places this provider in the 95th percentile of 60 critical care medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 256 | $198,020 |
| AdempasRiociguat | 12 | $162,687 |
| OfevNintedanib Esylate | 12 | $161,248 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 206 | $150,192 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 186 | $112,647 |
| Dupixent PenDupilumab | 20 | $75,803 |
| Spiriva RespimatTiotropium Bromide | 91 | $58,588 |
| NucalaMepolizumab | 14 | $55,306 |
| Pirfenidone | 57 | $38,227 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 228 | $34,503 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $34,055 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $29,950 |
| Tadalafil | 20 | $28,431 |
| Spiriva HandihalerTiotropium Bromide | 14 | $19,591 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 60 | $16,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $45 | $346,302313 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $446 | $324,364415 claims |
| BayerAdempas | $19 | $162,68712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $160 | $157,522235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 critical care medicine providers in Oregon.
Other critical care medicine in Bend
- Daniel HaggBend$679
- Ian SmithBend$470
- Tony AdamsBend$18
- Somnath GhoshMedford$11K
- Catherine HoughPortland$3K
- Rishi AroraMedford$3K
- Makoto UchiyamaTualatin$3K
- Jeffrey GoldPortland$2K
- Matthew NolandPortland$2K
- Brian DelmonacoCorvallis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.